The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19
- Registration Number
- NCT04558463
- Lead Sponsor
- Indonesia University
- Brief Summary
This study aims to analyze the effectiveness and safety of Avigan® (favipiravir) compared to Oseltamivir as an adjuvant therapy among adult COVID-19 patients. This study will be conducted in a hospital setting, recruiting adult COVID-19 patients with mild, moderate, and severe symptoms. Subjects will be randomly given Favipiravir or Oseltamivir as an adjuvant therapy to standard COVID-19 treatment. Patients will be followed up for 21 days after the first dose of intervention given. The primary outcomes of this study are the improvement of radiology results and RT PCR negative conversion during follow up. The secondary outcomes are adverse events, hospital length of stay (LOS), and Case fatality rate (CFR)
- Detailed Description
This open-label trial aims to analyze the effectiveness and safety of Avigan® (favipiravir) compared to Oseltamivir as an adjuvant therapy among adult COVID-19 patients. This study will be conducted in a hospital setting, recruiting adult COVID-19 patients with mild, moderate, and severe symptoms. Subjects will be randomly given Favipiravir or Oseltamivir as an adjuvant therapy to standard COVID-19 treatment. Patients will be followed up for 21 days after the first dose of intervention given. The primary outcomes of this study are clinical improvements determined by laboratory measurements and radiology results. The secondary outcomes are adverse events, hospital length of stay (LOS), and Case fatality rate (CFR)
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- adult patients aged 18-75 years old
- Patients with COVID-19 showing symptoms and confirmed with positive RT PCR test AND OR COVID-19 IgM/IgG rapid test
- No history of favipiravir or oseltamivir allergy
- Consented to participate in the trial.
- Pregnant women
- Breastfeeding mother
- Patients with markedly elevated liver enzyme (ALT and/or AST) of more than three times from baseline level
- Reduced kidney function with estimated glomerular filtration rate (eGFR) <30 mL/min OR serum creatinine > 2 mg/dL
- Patients with history of heart failure
- Tuberculosis infection that was treated with pyrazinamide
- Asthma that was treated with theophylline
- Type 2 diabetes that was treated with repaglinid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Favipiravir Favipiravir The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy Oseltamivir Oseltamivir 75mg The oseltamivir group was given oseltamivir for 7 days.
- Primary Outcome Measures
Name Time Method Clinical radiologic changes 14 days Changes of lung infiltrate in chest xray AND/OR GGO in chest CT scan after 14 days of follow up period This outcome measured will displayed as improvement/no changes/deterioration of radiologic examination results
Percentage of RT-PCR test convertion 14 days Convertion of RT-PCR swab result from positive to negative at the end of 14 days study follow up This outcome measured will displayed as convertion OR no conversion
- Secondary Outcome Measures
Name Time Method Case Fatality Rate (CFR) 14 days CFR is calculated from mortality rate during hospital admission
Hospital length of stay (LOS) 14 days Days of hospitalization from the first dose of intervention
Adverse event 14 days Mild to moderate adverse event serious adverse event such as sever allergy and increased transaminase enzyme \>3x normal limit
Trial Locations
- Locations (1)
Cipto Mangunkusumo National Referral Hospital
🇮🇩Jakarta, DKI Jakarta, Indonesia